{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:53:16Z","timestamp":1792450396327,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.eclinm.2024.102685","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T17:04:12Z","timestamp":1718989452000},"page":"102685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study"],"prefix":"10.1016","volume":"73","author":[{"given":"Long","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7884-3073","authenticated-orcid":false,"given":"Xin-xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.eclinm.2024.102685_bib1","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1182\/blood-2018-03-839753","article-title":"Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease","volume":"131","author":"Abla","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102685_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.clml.2019.06.013","article-title":"Rosai-dorfman disease: the md anderson cancer center experience","volume":"19","author":"Sathyanarayanan","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuke"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102685_bib3","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41375-023-02032-6","article-title":"Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease","volume":"37","author":"Chang","year":"2023","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102685_bib4","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/bloodadvances.2022009013","article-title":"Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor Trametinib: a multicenter analysis","volume":"7","author":"Aaroe","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.eclinm.2024.102685_bib5","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1001\/jamaoncol.2022.4432","article-title":"Outcomes after treatment with Cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status","volume":"8","author":"Abeykoon","year":"2022","journal-title":"JAMA Oncol"},{"issue":"12 Suppl","key":"10.1016\/j.eclinm.2024.102685_bib6","article-title":"Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: towards a new therapeutic approach","volume":"91","author":"Aouba","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.eclinm.2024.102685_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminhematol.2005.10.001","article-title":"Lenalidomide and thalidomide: mechanisms of action\u2014similarities and differences","volume":"42","author":"Anderson","year":"2005","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102685_bib8","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41375-022-01555-8","article-title":"Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent\/refractory adult Langerhans cell histiocytosis","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102685_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mayocpiqo.2018.11.002","article-title":"Confirmed efficacy of lenalidomide and dexamethasone in unresectable cutaneous facial Rosai-Dorfman-Destombes disease","volume":"3","author":"Al-Ghawas","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102685_bib10","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-021-04719-1","article-title":"Successful treatment of multisystemic Rosai-Dorfman disease with lenalidomide and dexamethasone: a case report","volume":"101","author":"Liu","year":"2022","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102685_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41375-021-01439-3","article-title":"Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis","volume":"36","author":"Chen","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102685_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3324\/haematol.2019.219626","article-title":"Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease","volume":"105","author":"Goyal","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102685_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/16078454.2021.1941552","article-title":"Long-time remission of laryngeal Rosai-Dorfman disease with thalidomide: a report of three cases","volume":"26","author":"Wei","year":"2021","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.eclinm.2024.102685_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24225","article-title":"Lenalidomide in the treatment of Rosai Dorfman disease--a first in use report","volume":"91","author":"Rubinstein","year":"2016","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.eclinm.2024.102685_bib16","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.3390\/cancers14215271","article-title":"Rosai-Dorfman disease between proliferation and neoplasia","volume":"14","author":"Elbaz","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102685_bib17","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.3324\/haematol.2019.216937","article-title":"Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1","volume":"105","author":"Razanamahery","year":"2020","journal-title":"Haematologica"},{"issue":"7512","key":"10.1016\/j.eclinm.2024.102685_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.eclinm.2024.102685_bib19","article-title":"Cereblon: a protein crucial to the multiple functions of immunomodulatory drugs as well as cell metabolism and disease generation","volume":"2017","author":"Shi","year":"2017","journal-title":"J\u00a0Immunol Res"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024002645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024002645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T12:46:57Z","timestamp":1721738817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024002645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":18,"alternative-id":["S2589537024002645"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102685","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102685","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102685"}}